Expression and clinical significance of SHP2 in gastric cancer

Journal of International Medical Research

Volumn 40, Issue 6, 2012, Pages 2083-2089

  Dong, S ^a   Li, F Q ^a   Zhang, Q ^a   Lv, K Z ^a   Yang, H L ^a   Gao, Y ^a   Yu, J R ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Gastric cancer; Gastric mucosal tissue; Immunohistochemistry; Nonreceptor type 11 (PTPN11); Protein tyrosine phosphatase; SRC homology 2 domain containing phosphatase (SHP 2)

Indexed keywords

MESSENGER RNA; PROTEIN TYROSINE PHOSPHATASE SHP 2;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC CODE; GENETIC CORRELATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEX DIFFERENCE; SHP2 GENE; STOMACH CANCER; STOMACH MUCOSA; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; TUMOR GENE; UPREGULATION;

EID: 84872234111     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/030006051204000605     Document Type: Article

References (26)

1. Qu CK: Role of the SHP-2 tyrosine phosphatase in cytokine-induced signaling and cellular response. Biochim Biophys Acta 2002; 1592: 297-301.
2. Ostman A, Hellberg C, Böhmer FD: Proteintyrosine phosphatases and cancer. Nat Rev Cancer 2006; 6: 307-320.
3. Motiwala T, Jacob ST: Role of protein tyrosine phosphatases in cancer. Prog Nucleic Acid Res Mol Biol 2006; 81: 297-329.
4. Tang TL, Freeman RM Jr, O'Reilly AM, et al: The SH2-containing protein-tyrosine phosphatase SH-PTP2 is required upstream of MAP kinase for early Xenopus development. Cell 1995; 80: 473-483.
5. Hadari YR, Kouhara H, Lax I, et al: Binding of Shp2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation. Mol Cell Biol 1998; 18: 3966-3973.
6. Chen B, Bronson RT, Klaman LD, et al: Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis. Nat Genet 2000; 24: 296-299.
7. You M, Yu DH, Feng GS: Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol Cell Biol 1999; 19: 2416-2424.
8. Tartaglia M, Martinelli S, Stella L, et al: Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet 2006; 78: 279-290.
9. Tartaglia M, Niemeyer CM, Shannon KM, et al: SHP-2 and myeloid malignancies. Curr Op Hematol 2004; 11: 44-50.
10. He G, Karin M: NF-γB and STAT3-key players in liver inflammation and cancer. Cell Res 2011; 21: 159-168.
11. Berasain C, Perugorria MJ, Latasa MU, et al: The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med (Maywood) 2009; 234: 713-725.
12. Su WP, Tu IH, Hu SW, et al: HER-2/neu raises SHP-2, stops IFN-γ anti-proliferation in bladder cancer. Biochem Biophys Res Commun 2007; 356: 181-186.
13. Zhou XD, Agazie YM: Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells. Cell Death Differ 2008; 15: 988-996.
14. Tsutsumi R, Takahashi A, Azuma T, et al: Focal adhesion kinase is a substrate and downstream effector of SHP-2 complexed with Helicobacter pylori CagA. Mol Cell Biol 2006; 26: 261-276.
15. Higashi H, Nakaya A, Tsutsumi R, et al: Helicobacter pylori CagA induces Rasindependent morphogenetic response through SHP-2 recruitment and activation. J Biol Chem 2004; 279: 17205-17216.
16. Saadat I, Higashi H, Obuse C, et al: Helicobacter pylori CagA targets PAR1/MARK kinase to disrupt epithelial cell polarity. Nature 2007; 447: 330-333.
17. Hatakeyama M: Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer 2004; 4: 688-694.
18. Blaser MJ, Perez-Perez GI, Kleanthous H, et al: Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995; 55: 2111-2115.
19. Sun XD, Mu R, Zhou YS, et al: Analysis of mortality rate of stomach cancer and its trend in twenty years in China. Zhonghua Zhong Liu Za Zhi 2004; 26: 4-9. [in Chinese, English abstract].
20. Coleman MP, Estève J, Damiecki P, et al: Trends in cancer incidence and mortality. IARC Sci Publ 1993: 1-806.
21. Seifert, G, Brocheriou, C, Cardesa, A, et al: WHO international histological classification of tumours. Tentative histological classification of salivary gland tumours. Pathol Res Pract 1990; 186: 555-581.
22. Wittekind, C (ed): TNM Supplement: a Commentary on Uniform Use, 4th edn. New York; Wiley-Blackwell, 2012.
23. Lu CD, Altieri DC, Tanigawa N: Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 1998; 58: 1808-1812.
24. Mineva I, Stamenova M, Gartner W, et al: Expression of the small heat shock protein alphaB-crystallin in term human placenta. Am J Reprod Immunol 2008; 60: 440-448.
25. Mohi MG, Neel BG: The role of Shp2 (PTPN11) in cancer. Curr Opin Genet Dev 2007; 17: 23-30.
26. Zhou X, Coad J, Ducatman B, et al: SHP2 is upregulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis. Histopathology 2008; 53: 389-402.